Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
[10-K] Ovid Therapeutics Inc. Files Annual Report | OVID SEC Filing - Form 10-K
Ovid Therapeutics Inc. filed its annual report on Form 10-K, detailing its biopharmaceutical focus on small molecule medicines for brain disorders. The company highlights its lead programs, OV329 for drug-resistant epilepsies and OV4071 as a KCC2 direct activator for psychoses and mood disorders, with clinical trials for both underway or planned. Ovid also discusses its financial position, ongoing operating losses, and recent private placement financings to support its research and development pipeline.